The therapeutic landscape of sickle cell disease (SCD) has expanded rapidly in recent years, with several novel approvals and numerous further agents under continued investigation. Abdullah Kutlar, MD, Augusta University, Augusta, GA, discusses the range of promising approaches currently being tested in early phase clinical trials. Fetal hemoglobin (HbF) induction strategies are a major area of investigation, with histone deacetylase (HDAC) inhibitor panobinostat and immunomodulatory agent pomalidomide both showing encouraging effects in Phase I investigations. Aside from pharmacologic HbF-induction, pyruvate kinase activators are another avenue of interest. Prof. Kutlar explains how these agents may produce beneficial results in SCD. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.